Alizapride

Summary

Alizapride (CHEMBL290194) is a phase-3 clinical-stage small molecule (ATC A03FA05) targeting DRD2; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A03FA05
• Targets: 1 (DRD2)
• Indications: 1 condition
• Chemistry: 315.37 Da · C16H21N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL290194
Name	Alizapride
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135413504
ATC	A03FA05
Molecular formula	C16H21N5O2
Molecular weight	315.37
InChIKey	KSEYRUGYKHXGFW-UHFFFAOYSA-N

SMILES: COC1=CC2=C(C=C1C(=O)NCC3CCCN3CC=C)NN=N2

IUPAC name: 6-methoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-3H-benzotriazole-5-carboxamide

Also known as: Alizaprida, Alizapride, Litican, Plitican, Superan, Vergentan, ALIZAPRIDE

Parent form; salt/anhydrous children: CHEMBL1896987

Patent coverage: 912 distinct patent families (3,823 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3,820 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
DRD2	D2 receptor	Antagonist		0%	P14416

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P61169	6.7	IC50	200	nM	CHEMBL_ACT_797081

Target pathways

Aggregated over 1 target gene(s): DRD2.

Top Reactome pathways

1 total, by targets touching each:

Pathway	Targets	Genes
Dopamine receptors	1	DRD2

Dominant GO biological processes

GO term	Targets
temperature homeostasis	1
response to hypoxia	1
response to amphetamine	1
nervous system process involved in regulation of systemic arterial blood pressure	1
regulation of heart rate	1
regulation of sodium ion transport	1
G protein-coupled receptor internalization	1
positive regulation of neuroblast proliferation	1
positive regulation of receptor internalization	1
intracellular calcium ion homeostasis	1
autophagy	1
adenylate cyclase-inhibiting dopamine receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuron-neuron synaptic transmission	1
neuroblast proliferation	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

297 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	DRD2
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	DRD2
AMIODARONE	ChEMBL	Phase 4 (approved)	DRD2
AMISULPRIDE	ChEMBL	Phase 4 (approved)	DRD2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2
AMLODIPINE	ChEMBL	Phase 4 (approved)	DRD2
AMODIAQUINE	ChEMBL	Phase 4 (approved)	DRD2
AMOXAPINE	ChEMBL	Phase 4 (approved)	DRD2
AMSACRINE	ChEMBL	Phase 4 (approved)	DRD2
APOMORPHINE	ChEMBL	Phase 4 (approved)	DRD2
ARFORMOTEROL	ChEMBL	Phase 4 (approved)	DRD2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2
ARMODAFINIL	ChEMBL	Phase 4 (approved)	DRD2
ASENAPINE	ChEMBL	Phase 4 (approved)	DRD2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	DRD2
AZATADINE	ChEMBL	Phase 4 (approved)	DRD2
AZELASTINE	ChEMBL	Phase 4 (approved)	DRD2
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	DRD2
BENPERIDOL	ChEMBL	Phase 4 (approved)	DRD2
BENZQUINAMIDE	ChEMBL	Phase 4 (approved)	DRD2
BENZTROPINE	ChEMBL	Phase 4 (approved)	DRD2
BEPRIDIL	ChEMBL	Phase 4 (approved)	DRD2
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	DRD2
BLONANSERIN	ChEMBL	Phase 4 (approved)	DRD2
BOSUTINIB	ChEMBL	Phase 4 (approved)	DRD2
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	DRD2
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	DRD2
BROMPERIDOL	ChEMBL	Phase 4 (approved)	DRD2
BUSPIRONE	ChEMBL	Phase 4 (approved)	DRD2
BUTRIPTYLINE	ChEMBL	Phase 4 (approved)	DRD2
CABERGOLINE	ChEMBL	Phase 4 (approved)	DRD2
CANNABIDIOL	ChEMBL	Phase 4 (approved)	DRD2
CARIPRAZINE	ChEMBL	Phase 4 (approved)	DRD2
CARVEDILOL	ChEMBL	Phase 4 (approved)	DRD2
CEFEPIME	ChEMBL	Phase 4 (approved)	DRD2
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	DRD2
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	DRD2
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	DRD2
CINACALCET	ChEMBL	Phase 4 (approved)	DRD2
CINNARIZINE	ChEMBL	Phase 4 (approved)	DRD2
CISAPRIDE	ChEMBL	Phase 4 (approved)	DRD2
CLEMASTINE	ChEMBL	Phase 4 (approved)	DRD2
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	DRD2
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	DRD2
CLOZAPINE	ChEMBL	Phase 4 (approved)	DRD2
CYCLOBENZAPRINE	ChEMBL	Phase 4 (approved)	DRD2
CYPROHEPTADINE	ChEMBL	Phase 4 (approved)	DRD2
DACOMITINIB	ChEMBL	Phase 4 (approved)	DRD2
DARIFENACIN	ChEMBL	Phase 4 (approved)	DRD2
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	DRD2
DESIPRAMINE	ChEMBL	Phase 4 (approved)	DRD2
DESLORATADINE	ChEMBL	Phase 4 (approved)	DRD2
DIBENZEPIN	ChEMBL	Phase 4 (approved)	DRD2
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	DRD2
DIPHENIDOL	ChEMBL	Phase 4 (approved)	DRD2
DISULFIRAM	ChEMBL	Phase 4 (approved)	DRD2
DOBUTAMINE	ChEMBL	Phase 4 (approved)	DRD2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	DRD2
DOPAMINE	ChEMBL	Phase 4 (approved)	DRD2